Proteomics International Laboratories (ASX:PIQ) said its PromarkerD predictive blood test has the potential to support earlier, more accurate identification of kidney disease risk in Aboriginal Australians with type 2 diabetes, according to a Monday filing with the Australian bourse.
The test delivered a 'rule out' rate of over 85% in Aboriginal participants, showing that a low score can reliably identify individuals unlikely to experience near-term kidney function decline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.